Nicola Giudici

Dr. Nicola Giudici

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2024 in World Journal of Clinical Oncology
Verified
Journal Article
Open access
NGNicola Giudici
Nicola Giudici
RSRoland Seiler
Roland Seiler
The majority of bladder cancers (BCs) are non-muscle invasive BCs (NMIBCs) and show the morphology of a conventional urothelial carcinoma (UC). Aberrant morphology is rare but can be observed. The classification and characterization of histologic subtypes (HS) in UC in BC have mainly been described in muscle invasive bladder cancer (MIBC). However, the currently used classification is applied for invasive urothelial neoplasm and therefore, also valid for a subset of NMIBC. The standard transurethral diagnostic work-up misses the presence of HS in NMIBC in a considerable percentage of patients and the real prevalence is not known. HS in NMIBC are associated with an aggressive phenotype. Consequently, clinical guidelines categorize HS of NMIBC as ”(very) high-risk” tumors and recommend offering radical cystectomy to these patients. Alternative strategies for bladder preservation can only be offered to highly selected patients and ideally within clinical trials. Novel treatment strategies and biomarkers have been established MIBC and NMIBC but have not been comprehensively investigated in the context of HS in NMIBC. Further evaluation prior to implementation into clinical practice is needed.

12 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NGNicola Giudici
Nicola Giudici
JBJennifer Blarer
Jennifer Blarer
NSNiranjan Sathianathen
Niranjan Sathianathen
FBFiona C. Burkhard
Fiona C. Burkhard
PWPatrick Yves Wuethrich
Patrick Yves Wuethrich
MFMarc Alain Furrer
Marc Alain Furrer
We performed a urine cytology analysis of a pharmacologically induced diuresis for the diagnosis of upper tract urothelial carcinoma. To evaluate the diagnostic value of cytology of pharmacologically forced diuresis, an initial cohort of 77 consecutive patients with primary upper tract urothelial carcinoma treated via radical surgery was enrolled. To evaluate pharmacologically forced diuresis cytology as a follow-up procedure, a second cohort of 1250 patients who underwent a radical cystectomy for bladder cancer was selected. In the first cohort, the sensitivity of cytology of pharmacologically forced diuresis in patients with invasive, high-grade, low-grade, and concomitant carcinoma in situ was 8%, 9%, 0%, and 14%, respectively. In the second cohort, cytology of pharmacologically forced diuresis was positive in 30/689 (4.3%) patients, in whom upper urinary tract recurrence was present in 21/30 (70%) of cases, and urethral recurrence was present in 8/30 (26%) of cases. As a follow-up tool, cytology of pharmacologically forced diuresis showed a sensitivity, specificity, and positive and negative predictive values of 60%, 99%, 70%, and 98%, respectively. Overall, as a diagnostic tool, the sensitivity of cytology of pharmacologically forced diuresis is slightly better in patients with invasive upper tract urothelial carcinoma and concomitant carcinoma in situ. As a follow-up method, positive cytology of pharmacologically forced diuresis is strongly related to cancer recurrence and can reveal urethral recurrence. Cytology of pharmacologically forced diuresis might be useful in cases with contraindications for imaging or when achieving endoscopic access to the upper urinary tract is difficult.

30 March 2026 in Journal of Robotic Surgery
Verified
Journal Article
Open access
PDF file
NGNicola Giudici
Nicola Giudici
RRRaphael Röthlisberger
Raphael Röthlisberger
NANicolas Arnold
Nicolas Arnold
DNDaniel Phat Nguyen
Daniel Phat Nguyen
AMAgostino Mattei
Agostino Mattei
BRBeat Roth
Beat Roth
To evaluate the impact of teaching during radical prostatectomy in a nationwide prospective registry, assessing whether teaching influences perioperative or pathological outcomes. Data were extracted from the Swiss Urology Prostatectomy Registry, a nationwide quality-monitoring program including all certified training centers. Teaching was defined as procedures performed by a supervised trainee as primary operator. Baseline and perioperative outcomes were compared descriptively, and multivariable regression models assessed associations between teaching status and perioperative and pathological outcomes. A total of 7,607 men underwent radical prostatectomy between 2020 and 2025, of whom 825 (10.8%) were teaching cases. In multivariable analyses, teaching operations were associated with a higher likelihood of any 30-day complication (OR 1.41; 95% CI 1.09–1.82; p = 0.008) and longer operative time, with an adjusted mean increase of 31 min (95% CI 26–37; p < 0.001). Teaching status was not associated with severe complications (Clavien–Dindo ≥ III; OR 0.62; 95% CI 0.24–1.36; p = 0.283), transfusion requirement (OR 1.56; 95% CI 0.36–4.60; p = 0.478), positive surgical margins (OR 0.99; 95% CI 0.81–1.22; p = 0.960), nerve-sparing (OR 1.12; 95% CI 0.90–1.39; p = 0.306), or lymph node yield (adjusted mean difference + 0.5 nodes; 95% CI − 0.3 to 1.4; p = 0.226). Teaching during radical prostatectomy is safe and does not compromise surgical or pathological outcomes. Although longer operative times were observed, supervised trainee involvement can be safely integrated into structured training programs.

27 June 2024 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Open access
NGNicola Giudici
Nicola Giudici
ASA. Schoch
A. Schoch
VGV. Genitsch
V. Genitsch
ARA. Rodriguez-Calero
A. Rodriguez-Calero
GTG.N. Thalmann
G.N. Thalmann
RSR. Seiler
R. Seiler
Introduction: Similar to bladder cancer, about one third of upper tract urothelial carcinoma (UTUC) present variant histology (VH). We aim to evaluate the incidence, clinical characteristics and the impact on outcomes of VH in UTUC. Methods: We consecutively enrolled 77 patients treated between 2009 and 2022 by radical surgery for UTUC from a secondary and a tertiary referral center. A pathology review of all specimens was performed by 1 independent uropathologist for each center. We compared pure UTUC and UTUC with VH and the accuracy of endoscopic biopsy. Descriptive and comparative analysis was performed to assess the association with clinical characteristics and the Kaplan–Meier estimator to compare outcomes. Results: Median follow-up after surgery was 51 months. VH was present in 21/77 (28%) patients and 4/21 (19%) patients had multiple variants. The most frequent VH was squamous 12/21 (57%), followed by glandular 7/21 (33%) and micropapillary 3/21 variants (14%). Neuroendocrine carcinoma was present in 2 patients. Nested variant was found in 1 patient. Muscle invasive tumor (≥pT2) was present in 30/56 (54%) patients with pure UTUC and in 18/21 (86%) patients with VH (P < 0.05). Presence of carcinoma in situ was seen in 24/56 (43%) patients with pure UTUC and in 16/21 (76%) with VH (P < 0.05). Cumulative 8/56 (14%) with pure UTUC had a nonintravesical recurrence (6 patients with local and 2 distant recurrence) compared to 8/21 (38%) (3 local, 3 nodal, 2 distant) in the subgroup with VH (P < 0.05). Opposite effect was noted for bladder recurrence: 60% for pure UTUC vs. 29% for tumors with VH (P < 0.05). Review of preoperative endoscopic biopsy did not show the presence of VH in any patients. Differences in outcomes did not reach significance: 3yr-OS 63% vs. 42% (P 0.28) and 3yr-CSS 77% vs. 50% (P 0.7). Conclusion: Almost a third of UTUC present VH. Presence of VH is related to more aggressive tumor characteristics and associated with unfavorable outcomes. Due to a higher rate of extravesical recurrences in UTUC with VH, Follow-up controls should include cross sectional imaging and cystoscopy.

25 March 2026 in World Journal of Urology
Verified
Journal Article
Open access
JMJonas Mudlagk
Jonas Mudlagk
OMOdile Minder
Odile Minder
AMAshkan Mortezavi
Ashkan Mortezavi
BBBenjamin Bulling
Benjamin Bulling
JCJulian Cornelius
Julian Cornelius
NGNicola Giudici
Nicola Giudici
Purpose: Prostate cancer (PCa) diagnosis relies on PSA testing, but its low specificity leads to overdiagnosis. Stockholm3 may improve diagnostic accuracy. This study evaluated the performance of Stockholm3 for detecting clinically significant PCa (csPCa), defined as ISUP grade ≥ 2 on biopsy, in a real-world, non-referral Swiss cohort. Methods: Retrospective analysis of a prospective registry (2023–2025) at a non-referral urology practice in Switzerland. Initial screening was performed in men with PSA > 1.5 ng/mL or a suspicious digital rectal examination. Patients who underwent Stockholm3 and biopsy were included. We compared Stockholm3 with PSA, PSA density, and the SWOP risk calculator for the detection of csPCa in a pre-MRI diagnostic setting. Results: We included 178 men (median age 65 years, IQR: 60.0–70.0). Among them, 60/178 (33.7%) had csPCa. Stockholm3 ≥ 15 showed sensitivity 0.78 (95% CI 0.67–0.88), specificity 0.44 (95% CI 0.35–0.54), and AUC 0.68 (95% CI 0.60–0.77). SWOP score > 4% showed sensitivity 0.42 (95% CI 0.30–0.55), specificity 0.78 (95% CI 0.70–0.85), and AUC 0.68 (95% CI 0.59–0.76). Both tests outperformed PSA > 3 ng/mL and PSA density > 0.15 ng/mL², with AUCs of 0.52 (95% CI 0.48–0.56) and 0.57 (95% CI 0.50–0.64), respectively. Decision curve analysis and calibration curves favored Stockholm3 over SWOP. Conclusions: In a non-referral setting, Stockholm3 confirmed good diagnostic performance for csPCa. These findings support its use as part of the primary diagnostic work-up in similar clinical settings.

9 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
NGNicola Giudici
Nicola Giudici
JBJennifer Blarer
Jennifer Blarer
NSNiranjan Sathianathen
Niranjan Sathianathen
FBFiona C. Burkhard
Fiona C. Burkhard
PWPatrick Yves Wuethrich
Patrick Yves Wuethrich
MFMarc A. Furrer
Marc A. Furrer
We performed urine cytology analysis of a pharmacologically induced diuresis for diagnostics of upper tract urothelial carcinoma. To evaluate the diagnostic value of cytology of pharmacologically forced diuresis, a first cohort of 77 consecutive patients with primary upper tract urothelial carcinoma treated with radical surgery was enrolled. To evaluate pharmacologically forced diuresis cytology as follow-up procedure, a second cohort of 1250 patients who underwent radical cystectomy for bladder cancer was selected. In the first cohort, sensitivity of cytology of pharmacologically forced diuresis in patients with invasive, high-grade, low-grade, and concomitant carcinoma in situ was 8%, 9%, 0% and 14%, respectively. In the second cohort, cytology of pharmacologically forced diuresis was positive in 30/689 (4.3%) of patients, in whom upper urinary tract recurrence was present in 21/30 (70%) and urethral recurrence in 8/30 (26%) of cases. As a follow-up tool, cytology of pharmacologically forced diuresis showed a sensitivity, specificity, and positive and negative predictive value of 60%, 99%, 70% and 98%, respectively. Summarized, as diagnostic tool, sensitivity of cytology of pharmacologically forced diuresis is slightly better in patients with invasive upper tract urothelial carcinoma and concomitant carcinoma in situ. As follow-up method, positive cytology of pharmacologically forced diuresis is strongly related to cancer recurrence and can reveal urethral recurrence. cytology of pharmacologically forced diuresis might be useful in patients with contraindications for imaging or with difficult endoscopic access to the upper urinary tract.